Price alert —
Sign in to get a one-time email the moment SYK crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · SYK
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6.0B | $0.7B | $0.9B | $0.4B | 12.4% | 15.5% |
| 2025-12-31 | $7.2B | $0.8B | $1.8B | $1.9B | 11.8% | 25.3% |
| 2025-09-30 | $6.1B | $0.9B | $1.2B | $1.4B | 14.2% | 19.9% |
| 2025-06-30 | $6.0B | $0.9B | $1.2B | $0.9B | 14.7% | 19.4% |
| 2025-03-31 | $5.9B | $0.7B | $0.9B | $0.1B | 11.1% | 14.9% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare SYK vs peers
Line SYK up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with SYK
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-04-30 | 2.60 | 2.98 | -12.9% | -6.5% |
| 2026-01-29 | 4.47 | 4.40 | +1.7% | +4.3% |
| 2025-10-30 | 3.19 | 3.13 | +1.9% | -3.5% |
| 2025-07-31 | 3.13 | 3.07 | +1.9% | -3.8% |
| 2025-05-01 | 2.84 | 2.73 | +4.0% | +1.1% |
| 2025-01-28 | 4.01 | 3.87 | +3.5% | -1.0% |
| 2024-10-29 | 2.87 | 2.77 | +3.5% | +1.2% |
| 2024-07-30 | 2.81 | 2.79 | +0.7% | -0.8% |
| 2024-04-30 | 2.50 | 2.36 | +6.1% | -2.5% |
| 2024-01-30 | 3.46 | 3.27 | +5.9% | +6.0% |
| 2023-11-02 | 2.46 | 2.44 | +0.9% | -0.7% |
| 2023-08-03 | 2.54 | 2.38 | +6.8% | +2.9% |
| 2023-05-01 | 2.14 | 2.00 | +6.9% | -2.0% |
| 2023-01-31 | 3.00 | 2.84 | +5.8% | +9.9% |
| 2022-10-31 | 2.12 | 2.23 | -4.8% | -4.0% |
| 2022-07-26 | 2.25 | 2.28 | -1.5% | +3.6% |
| 2022-04-28 | 1.97 | 1.92 | +2.7% | -4.3% |
| 2022-01-27 | 2.71 | 2.72 | -0.5% | +1.2% |
| 2021-10-28 | 2.20 | 2.28 | -3.6% | -0.9% |
| 2021-07-27 | 2.25 | 2.13 | +5.9% | +0.1% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| SYK ★ | $123B | 37.0 | 19.1 | 4.9 | 19.5 | 5.3 | 64.7% | 2.6% | 14.2% | 3.56% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 35.84%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 27,602,049 | 7.20% |
| Vanguard Capital Management LLC | 22,383,181 | 5.84% |
| Greenleaf Trust | 15,938,070 | 4.16% |
| JPMORGAN CHASE & CO | 15,596,897 | 4.07% |
| State Street Corporation | 15,349,165 | 4.00% |
| Price (T.Rowe) Associates Inc | 10,037,137 | 2.62% |
| Vanguard Portfolio Management LLC | 8,334,244 | 2.17% |
| Wellington Management Group, LLP | 8,121,707 | 2.12% |
| Geode Capital Management, LLC | 7,748,294 | 2.02% |
| Morgan Stanley | 6,297,555 | 1.64% |
Insider activity · 90d
0 buys / 14 sells · ratio 0.0 · Finnhub
- Stiles Spencer S G 76,027
- Fletcher Robert S SELL 10,582 @ $310.22
- Fletcher Robert S SELL 10,707 @ $308.79
- Fletcher Robert S SELL 10,965 @ $307.30
- Fletcher Robert S SELL 12,032 @ $306.56
- Fletcher Robert S SELL 14,841 @ $305.66
- Fletcher Robert S SELL 15,006 @ $304.23
- STRYKER RONDA E SELL 2,600,815 @ $315.11
- STRYKER RONDA E SELL 1,924,880 @ $314.38
- STRYKER RONDA E SELL 1,935,287 @ $313.35
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-06-26 | 8-K | view · |
| 4 | 2026-06-02 | FORM 4 | view · |
| 4 | 2026-05-29 | FORM 4 | view · |
| 4 | 2026-05-28 | FORM 4 | view · |
| 8-K | 2026-05-20 | 8-K | view · |
| 4 | 2026-05-12 | FORM 4 | view · |
| 10-Q | 2026-05-11 | 10-Q | view · |
| 4 | 2026-05-08 | FORM 4 | view · |
| 4 | 2026-05-08 | FORM 4 | view · |
| 4 | 2026-05-08 | FORM 4 | view · |
| 4 | 2026-05-08 | FORM 4 | view · |
| 4 | 2026-05-08 | FORM 4 | view · |
| 4 | 2026-05-08 | FORM 4 | view · |
| 4 | 2026-05-08 | FORM 4 | view · |
| 4 | 2026-05-08 | FORM 4 | view · |
| 4 | 2026-05-08 | FORM 4 | view · |
| 4 | 2026-05-08 | FORM 4 | view · |
| 4 | 2026-05-08 | FORM 4 | view · |
| 8-K | 2026-05-08 | 8-K | view · |
| 8-K | 2026-04-30 | 8-K | view · |
| 4 | 2026-03-24 | FORM 4 | view · |
| 4 | 2026-03-24 | FORM 4 | view · |
| 4 | 2026-03-24 | FORM 4 | view · |
| 4 | 2026-03-24 | FORM 4 | view · |
| 4 | 2026-03-24 | FORM 4 | view · |
| 4 | 2026-03-24 | FORM 4 | view · |
| 4 | 2026-03-24 | FORM 4 | view · |
| 4 | 2026-03-24 | FORM 4 | view · |
| 4 | 2026-03-24 | FORM 4 | view · |
| DEF 14A | 2026-03-23 | DEF 14A | view · |
| 8-K | 2026-03-23 | 8-K | view · |
| 8-K | 2026-03-12 | 8-K | view · |
| 8-K | 2026-03-11 | 8-K | view · |
| 4 | 2026-03-11 | FORM 4 | view · |
| 4 | 2026-03-11 | FORM 4 | view · |
| 4 | 2026-03-11 | FORM 4 | view · |
| 4 | 2026-03-11 | FORM 4 | view · |
| 4 | 2026-03-11 | FORM 4 | view · |
| 4 | 2026-03-11 | FORM 4 | view · |
| 4 | 2026-02-24 | FORM 4 | view · |
| 4 | 2026-02-18 | FORM 4 | view · |
| 10-K | 2026-02-11 | 10-K | view · |
| 4 | 2026-02-06 | FORM 4 | view · |
| 4 | 2026-02-06 | FORM 4 | view · |
| 4 | 2026-02-06 | FORM 4 | view · |
| 4 | 2026-02-06 | FORM 4 | view · |
| 4 | 2026-02-06 | FORM 4 | view · |
| 4 | 2026-02-06 | FORM 4 | view · |
| 4 | 2026-02-06 | FORM 4 | view · |
| 4 | 2026-02-06 | FORM 4 | view · |
| 4 | 2026-02-06 | FORM 4 | view · |
| 4 | 2026-02-06 | FORM 4 | view · |
| 4 | 2026-02-06 | FORM 4 | view · |
| 4 | 2026-02-06 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 8-K | 2026-01-29 | 8-K | view · |
| 4 | 2026-01-16 | FORM 4 | view · |
| 4 | 2026-01-14 | FORM 4 | view · |
| 4 | 2025-12-17 | FORM 4 | view · |
About SYK
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, …
Options picks · SYK
ITM + OTM ideas from the latest scanLoading…
Congress trades · SYK
STOCK Act disclosuresLoading…
SEC filings & insiders · SYK
EDGAR · liveLoading…
Holders · SYK
Institutions & insider activityLoading…